Table 2.
Univariate and multivariate analysis evaluating the relationship between long-term responders and clinicopathological factors
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 9 5 % CI | P value | |
| Age > 70 | 0.83 | 0.36–1.88 | 0.66 | |||
| Gender, male | 0.83 | 0.43–1.58 | 0.57 | |||
| Histology clear-cell RCC | 0.79 | 0.58–1.06 | 0.12 | |||
| Previous nephrectomy, Yes | 8.64 | 2.04–36.43 | 0.003 | 7.4 | 1.66–33.5 | 0.009 |
| ECOG PS ≥ 1 | 0.52 | 0.29–0.93 | 0.028 | 0.51 | 0.26–0.98 | 0.04 |
| Sarcomatoid feature, Yes | 0.79 | 0.52–1.19 | 0.26 | |||
| IMDC score intermediate-poor | 0.40 | 0.22–0.72 | 0.002 | |||
| Metastatic sites, n (%) | ||||||
| Lung | 0.97 | 0.53–1.75 | 0.92 | |||
| Liver | 0.40 | 0.15–1.07 | 0.07 | |||
| Nodal | 0.81 | 0.45–1.45 | 0.48 | |||
| Bone | 0.43 | 0.22–0.82 | 0.01 | |||
| Brain | 0.10 | 0.01–0.75 | 0.02 | 0.08 | 0.01–0.63 | 0.01 |
| Line of therapy after TKI > 1, n (%) | 0.11 | 0.05–0.21 | 0.001 | 0.26 | 0.13–0.5 | 0.001 |
ECOG PS: Eastern Cooperative Oncology Group performance status scale; RCC: Renal cell carcinoma; TKI: Tyrosine kinase inhibitor; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium.